Home/Filings/4/0001385508-23-000073
4//SEC Filing

Ruth Matthew R. 4

Accession 0001385508-23-000073

CIK 0001385508other

Filed

Mar 2, 7:00 PM ET

Accepted

Mar 3, 9:22 AM ET

Size

12.5 KB

Accession

0001385508-23-000073

Insider Transaction Report

Form 4
Period: 2023-03-02
Ruth Matthew R.
Chief Commercial Officer
Transactions
  • Disposition to Issuer

    Common Stock

    2023-03-02$20.00/sh19,250$385,00010,666 total
  • Disposition to Issuer

    Common Stock

    2023-03-02$20.00/sh10,666$213,3200 total
  • Award

    Common Stock

    2023-03-02+2,0002,000 total
  • Disposition to Issuer

    Common Stock

    2023-03-02$20.00/sh2,000$40,0000 total
  • Disposition to Issuer

    Stock Option (right to buy)

    2023-03-0250,0000 total
    Exercise: $16.41From: 2022-07-12Exp: 2031-07-11Common Stock (50,000 underlying)
Footnotes (5)
  • [F1]Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Indivior Inc., and Olive Acquisition Subsidiary, Inc., dated as of November 13, 2022 (the "Merger Agreement"), in exchange for a cash payment of $20.00 per share without interest thereon (the "Merger Consideration"). The number of shares disposed of reflect 11,736 shares of Common Stock upon the acceleration of vesting of restricted stock units in accordance with the Merger Agreement.
  • [F2]Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration.
  • [F3]2,000 shares are represented by performance stock units ("PSUs"), the vesting accelerated in accordance with the Merger Agreement. Each PSU represents the Reporting Person's right to receive one share of Common Stock of Issuer.
  • [F4]Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration. The number of shares disposed of reflects 2,000 shares of Common Stock upon the acceleration of vesting of performance stock units in accordance with the Merger Agreement.
  • [F5]The option was cancelled pursuant to the Merger Agreement in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares.

Issuer

OPIANT PHARMACEUTICALS, INC.

CIK 0001385508

Entity typeother

Related Parties

1
  • filerCIK 0001872022

Filing Metadata

Form type
4
Filed
Mar 2, 7:00 PM ET
Accepted
Mar 3, 9:22 AM ET
Size
12.5 KB